Intermittent androgen suppression for rising PSA level after radiotherapy.

ABSTRACT:

Background

Intermittent androgen deprivation for prostate-specific antigen (PSA) elevation after radiotherapy may improve quality of life and delay hormone resistance. We assessed overall survival with intermittent versus continuous androgen deprivation in a noninferiority randomized trial.

Methods

We enrolled patients with a PSA level greater than 3 ng per milliliter more than 1 year after primary or salvage radiotherapy for localized prostate cancer. Intermittent treatment was provided in 8-month cycles, with nontreatment periods determined according to the PSA level. The primary end point was overall survival. Secondary end points included quality of life, time to castration-resistant disease, and duration of nontreatment intervals.

Results

Of 1386 enrolled patient

SUBMITTER: Crook JM 

PROVIDER: S-EPMC3521033 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature